.png)
Primary Sclerosing Cholangitis Treatment Market by Type and Application- Global Industry Analysis & Forecast to 2027
Published On : December 2020 Pages : 169 Category: Medical Devices Report Code : HC1214080
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Primary Sclerosing Cholangitis Treatment Market by Type(UDCA Drugs,Liver Transplantation Operation,PSC Drugs)Application (Clinics,Hospital,Other)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Primary Sclerosing Cholangitis Treatment Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Essential sclerosing cholangitis (PSC) is a constant illness of the liver and gallbladder, described by irritation and scarring of the bile pipes from inside and outside, which typically permit bile to deplete from the gallbladder.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Glenmark
- Allergan
- Bruschettini
- Impax Laboratories
- Teva Pharmaceuticals
- Mylan
- Epic Pharma
- Dr. Falk Pharma
- Mitsubishi Tanabe Pharma
- Lannett
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Primary Sclerosing Cholangitis Treatment Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o UDCA Drugs
o Liver Transplantation Operation
o PSC Drugs
· Primary Sclerosing Cholangitis Treatment Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Clinics
o Hospital
· Primary Sclerosing Cholangitis Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Glenmark
o Allergan
o Bruschettini
o Impax Laboratories
o Teva Pharmaceuticals
o Mylan
o Epic Pharma
o Dr. Falk Pharma
o Mitsubishi Tanabe Pharma
o Lannett
· Primary Sclerosing Cholangitis Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Primary Sclerosing Cholangitis Treatment Market, By Country
o U.S. Primary Sclerosing Cholangitis Treatment Market
o Canada Primary Sclerosing Cholangitis Treatment Market
o Mexico Primary Sclerosing Cholangitis Treatment Market
o Europe
§ Europe Primary Sclerosing Cholangitis Treatment Market, By Country
· Germany Primary Sclerosing Cholangitis Treatment Market
o UK Primary Sclerosing Cholangitis Treatment Market
o France Primary Sclerosing Cholangitis Treatment Market
o RussiaPrimary Sclerosing Cholangitis Treatment Market
o Italy Primary Sclerosing Cholangitis Treatment Market
o Rest of Europe Primary Sclerosing Cholangitis Treatment Market
o Asia-Pacific
§ Asia-Pacific Primary Sclerosing Cholangitis Treatment Market, By Country
o ChinaPrimary Sclerosing Cholangitis Treatment Market
o Japan Primary Sclerosing Cholangitis Treatment Market
o South KoreaPrimary Sclerosing Cholangitis Treatment Market
o India Primary Sclerosing Cholangitis Treatment Market
o Southeast AsiaPrimary Sclerosing Cholangitis Treatment Market
o Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Market
o South America
§ South AmericaPrimary Sclerosing Cholangitis Treatment Market
o Brazil Primary Sclerosing Cholangitis Treatment Market
o ArgentinaPrimary Sclerosing Cholangitis Treatment Market
o ColumbiaPrimary Sclerosing Cholangitis Treatment Market
o Rest of South America Primary Sclerosing Cholangitis Treatment Market
o Middle East and Africa
§ Middle East and AfricaPrimary Sclerosing Cholangitis Treatment Market
o Saudi ArabiaPrimary Sclerosing Cholangitis Treatment Market
o UAEPrimary Sclerosing Cholangitis Treatment Market
o EgyptPrimary Sclerosing Cholangitis Treatment Market
o NigeriaPrimary Sclerosing Cholangitis Treatment Market
o South Africa Primary Sclerosing Cholangitis Treatment Market
o Rest of MEA Primary Sclerosing Cholangitis Treatment Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Primary Sclerosing Cholangitis Treatment Market, By Type
5.1. Introduction
5.2. Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Type (2017-2021)
5.2.1. Global Primary Sclerosing Cholangitis Treatment Revenue and Revenue Share by Type (2017-2021)
5.3. UDCA Drugs
5.3.1. Global UDCA Drugs Revenue and Growth Rate (2017-2021)
5.4. Liver Transplantation Operation
5.4.1. Global Liver Transplantation Operation Revenue and Growth Rate (2017-2021)
5.5. PSC Drugs
5.5.1. Global PSC Drugs Revenue and Growth Rate (2017-2021)
6. Primary Sclerosing Cholangitis Treatment Market, By Application
6.1. Introduction
6.2. Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Application (2017-2021)
6.2.1. Global Primary Sclerosing Cholangitis Treatment Revenue and Revenue Share by Application (2017-2021)
6.3. Clinics
6.3.1. Global Clinics Revenue and Growth Rate (2017-2021)
6.4. Hospital
6.4.1. Global Hospital Revenue and Growth Rate (2017-2021)
6.5. Other
6.5.1. Global Other Revenue and Growth Rate (2017-2021)
7. Primary Sclerosing Cholangitis Treatment Market, By Region
7.1. Introduction
7.2. Global Primary Sclerosing Cholangitis Treatment Revenue and Market Share by Regions
7.2.1. Global Primary Sclerosing Cholangitis Treatment Revenue by Regions (2017-2021)
7.3. North America Primary Sclerosing Cholangitis Treatment by Countries
7.3.1. North America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2021)
7.3.2. North America Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Primary Sclerosing Cholangitis Treatment by Countries
7.4.1. Europe Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2021)
7.4.2. Europe Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Primary Sclerosing Cholangitis Treatment by Countries
7.5.1. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Primary Sclerosing Cholangitis Treatment by Countries
7.6.1. South America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2021)
7.6.2. South America Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Primary Sclerosing Cholangitis Treatment by Countries
7.7.1. Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Glenmark
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Allergan
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Bruschettini
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Impax Laboratories
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Teva Pharmaceuticals
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Mylan
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Epic Pharma
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Dr. Falk Pharma
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Mitsubishi Tanabe Pharma
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Lannett
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.1. Global Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Primary Sclerosing Cholangitis Treatment Market Forecast by Regions (2022-2027)
9.2.1. North America Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.1.1. United States Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.1.2. Canada Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.1.3. Mexico Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2. Europe Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.1. Germany Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.2. France Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.3. UK Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.4. Russia Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.5. Italy Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.1. China Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.2. Japan Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.3. Korea Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.4. India Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.4. South America Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.4.1. Brazil Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.4.2. Argentina Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.4.3. Columbia Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.4.4. Rest of South America Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.3. Egypt Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.4. Nigeria Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.5. South Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.6. Turkey Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2022-2027)
9.3. Primary Sclerosing Cholangitis Treatment Market Forecast by Type (2022-2027)
9.3.1. Primary Sclerosing Cholangitis Treatment Forecast by Type (2022-2027)
9.3.2. Primary Sclerosing Cholangitis Treatment Market Share Forecast by Type (2022-2027)
9.4. Primary Sclerosing Cholangitis Treatment Market Forecast by Application (2022-2027)
9.4.1. Primary Sclerosing Cholangitis Treatment Forecast by Application (2022-2027)
9.4.2. Primary Sclerosing Cholangitis Treatment Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Primary Sclerosing Cholangitis Treatment Revenue and Revenue Share by Type (2017-2019)
Figure Global UDCA Drugs Revenue and Growth Rate (2017-2019)
Figure Global Liver Transplantation Operation Revenue and Growth Rate (2017-2019)
Figure Global PSC Drugs Revenue and Growth Rate (2017-2019)
Table Global Primary Sclerosing Cholangitis Treatment Revenue and Revenue Share by Application (2017-2019)
Figure Global Clinics Revenue and Growth Rate (2017-2019)
Figure Global Hospital Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Primary Sclerosing Cholangitis Treatment Revenue by Regions (2017-2019)
Figure North America Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure North America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2019)
Figure North America Primary Sclerosing Cholangitis Treatment by Countries (2017-2019)
Figure North America Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure United States Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Canada Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Mexico Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Europe Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Primary Sclerosing Cholangitis Treatment by Countries (2017-2019)
Figure Europe Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Germany Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure France Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure UK Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Russia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Italy Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Rest of Europe Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Primary Sclerosing Cholangitis Treatment by Countries (2017-2019)
Figure Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure China Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Japan Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Korea Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure India Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Southeast Asia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure South America Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2019)
Figure South America Primary Sclerosing Cholangitis Treatment by Countries (2017-2019)
Figure South America Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Brazil Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Argentina Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Columbia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Rest of South America Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Primary Sclerosing Cholangitis Treatment by Countries (2017-2019)
Figure Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Egypt Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Nigeria Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure South Africa Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Turkey Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table Glenmark Primary Sclerosing Cholangitis Treatment Financial Overview
Table Allergan Primary Sclerosing Cholangitis Treatment Financial Overview
Table Bruschettini Primary Sclerosing Cholangitis Treatment Financial Overview
Table Impax Laboratories Primary Sclerosing Cholangitis Treatment Financial Overview
Table Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Financial Overview
Table Mylan Primary Sclerosing Cholangitis Treatment Financial Overview
Table Epic Pharma Primary Sclerosing Cholangitis Treatment Financial Overview
Table Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Financial Overview
Table Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Financial Overview
Table Lannett Primary Sclerosing Cholangitis Treatment Financial Overview
Figure Global Primary Sclerosing Cholangitis Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Primary Sclerosing Cholangitis Treatment Market Forecast by Regions (2019-2027)
Figure North America Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure United States Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Canada Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Mexico Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Europe Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Germany Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure France Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure UK Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Russia Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Italy Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Rest of Europe Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure China Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Japan Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Korea Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure India Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Southeast Asia Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure South America Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Brazil Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Argentina Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Columbia Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Rest of South America Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Egypt Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Nigeria Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure South Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Turkey Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Forecast (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Forecast by Type (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Market Share Forecast by Type (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Forecast by Type (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Forecast by Application (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Market Share Forecast by Application (2019-2027)
Figure Global Primary Sclerosing Cholangitis Treatment Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|